Enlivex Doses First Patient in Phase I Solid Tumor Trial
Ticker: ENLV · Form: 6-K · Filed: Nov 14, 2024 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, drug-development, phase-i
TL;DR
Enlivex dosed first patient in Phase I solid tumor trial, initial follow-up complete.
AI Summary
Enlivex Therapeutics Ltd. announced on November 14, 2024, the completion of dosing and initial follow-up for the first patient in its Phase I clinical trial. This trial is evaluating the safety and tolerability of Allocetra, their cell therapy candidate, in patients with advanced solid tumors.
Why It Matters
This marks a significant step in Enlivex's development of Allocetra, potentially validating its therapeutic approach for advanced solid tumors.
Risk Assessment
Risk Level: medium — Phase I trials are early-stage and carry inherent risks regarding drug efficacy and safety, with a high failure rate for new drug candidates.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- November 14, 2024 (date) — Announcement Date
- Allocetra (drug) — Cell therapy candidate
- Phase I (trial_phase) — Clinical trial stage
- Israel (country) — Company domicile
FAQ
What is the primary purpose of the Phase I trial for Allocetra?
The Phase I trial is evaluating the safety and tolerability of Allocetra in patients with advanced solid tumors.
When was the announcement regarding the Phase I trial made?
The announcement was made on November 14, 2024.
What is the name of Enlivex Therapeutics' cell therapy candidate?
Enlivex Therapeutics' cell therapy candidate is named Allocetra.
In which patient population is Allocetra being tested in this Phase I trial?
Allocetra is being tested in patients with advanced solid tumors.
What is the company's country of incorporation?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Filing Stats: 241 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-11-14 08:01:27
Filing Documents
- ea0221178-6k_enlivex.htm (6-K) — 9KB
- ea022117801ex99-1_enlivex.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-097818.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: November 14, 2024 2